April 2012- Volume 8, Issue 4
April 2012
In this Issue
Global News
Coming into the light
Coming into the light
Lonza signs Light Path discovery agreement with LegoChem to provide preclinical material of novel therapeutic compound
Hot target for HCV
Hot target for HCV
Enanta Pharmaceuticals, Novartis collaborate on hepatitis C virus drug in deal worth up to $440 million
Jumping on JAK1
Jumping on JAK1
Abbott and Galapagos collaborate on novel oral therapy for autoimmune diseases
Antibody potential a 'SIMPLE' fact
Antibody potential a 'SIMPLE' fact
Human monoclonal antibodies focus of new Shire, arGEN-X alliance
A new sun rises for vaccines
A new sun rises for vaccines
GSK, Daiichi Sankyo announce Japanese joint venture
Omics & Systems Biology
Acquiring a peer across the Atlantic
Acquiring a peer across the Atlantic
Abcam to buy San Francisco-based antibody business Epitomics with even mix of cash and shares
Sanofi cultivates 'research ecosystem'
Sanofi cultivates 'research ecosystem'
Pharma partners with Spain’s Centre for Genomic Regulation to explore potential of translational medicine
Delivering genomics to routine care
Delivering genomics to routine care
Foundation Medicine announces collaboration with Array BioPharma to help better target patients for certain cancer treatments
Ready and aiming
Ready and aiming
RNAi therapeutics get new boost from Arrowhead Research and Axolabs strategic alliance
MJFF showcases Parkinson’s disease advances by Kinemed
MJFF showcases Parkinson’s disease advances by Kinemed
KineMed Inc. recently announced that it has been awarded funding by the Michael J. Fox Foundation (MJFF) Industry Partnering Program
Bridge over the Charles River
Bridge over the Charles River
The Bridge Project, a landmark cancer research initiative, pairs Koch Institute, Dana-Farber/Harvard Cancer Center
Contract Services
Making genomic research whole
Making genomic research whole
Mayo Clinic taps Complete Genomics to provide outsources whole-genome sequencing
Charles River rolls toward improved viral clearance studies
Charles River rolls toward improved viral clearance studies
CRO licenses EMD Millipore technology to improve drug product safety
An immunological decision
An immunological decision
Selventa, Janssen form research agreement targeted toward treating immunological disease
Sister companies trod biosimilar path
Sister companies trod biosimilar path
Celerion and Ricerca Biosciences form the Biosimilars Alliance to provide clients a more effective development path for biosimilars
BGI on board with ‘Novo Nordisk Way’
BGI on board with ‘Novo Nordisk Way’
Denmark’s Novo Nordisk and China’s BGI establish global collaboration framework to accelerate growth
Tools & Technology
A biopharmaceutical bonanza
A biopharmaceutical bonanza
GE Healthcare acquires Xcellerex as it looks to broaden capabilities in growing biopharmaceutical market and provide start-to-finish offerings
Across all domains
Across all domains
Certara acquires Simcyp, boosting preclinical research capabilities
A rock-solid partnership
A rock-solid partnership
Rockland, NCI collaboration announces release of new antibodies
Comparing apples to Apples
Comparing apples to Apples
IO Informatics and Sage-N Research announce partnership to discover potential biomarkers, disease causes and prevention
TIBCO, ChemAxon integrate analytics data management applications
TIBCO, ChemAxon integrate analytics data management applications
TIBCO Software Inc. and ChemAxon, providers of chemical software development platforms and desktop applications for the biotechnology and pharmaceutical industries, announced in February the full integration of the TIBCO Spotfire Analytics Platform with ChemAxon’s Instant JChem data management application
Diagnostics
Abbott and Merck go FISH
Abbott and Merck go FISH
Companies collaborate to develop FISH-based companion diagnostic test for cancer therapy
Translating a pilot into a full collaboration
Translating a pilot into a full collaboration
Molecular Response and OncoMed sign collaboration deal that expands existing relationship in translational oncology
Getting an Angle on cancer
Getting an Angle on cancer
Parsortix signs research agreement with Paterson Institute
Reinforcing their lines
Reinforcing their lines
Illumina stands fast as Roche continues takeover attempt
Special Reports
Everything old is new again
Everything old is new again
Drug repositioning provides cost savings, shortcuts
Feature
Great minds think alike
Great minds think alike
Experimental Bio show brings together numerous specialty societies to advance knowledge in drug discovery, development and more
Research & Development
Joined together by JNK
Joined together by JNK
Scripps Institute and OPKO Health announce deal for promising Parkinson’s therapy
Crossing the 'Valley of Death'
Crossing the 'Valley of Death'
The Wistar Institute and the Moulder Center join forces to accelerate drug development
University of Pittsburgh and UPMC partner with J&J corporate office
University of Pittsburgh and UPMC partner with J&J corporate office
The University of Pittsburgh and UPMC have entered into a partnership with Johnson & Johnson Corporate Office of Science and Technology (COSAT) to support translational research
Being flexible with Fleximer
Being flexible with Fleximer
Mersana, Endo collaborate on antibody-drug conjugate development
Heavy ADME
Heavy ADME
Concert Pharmaceuticals will partner with Avanir Pharmaceuticals to develop and commercialize deuterium-modified dextromethorphan for nervous system disorders
Pharma pink-slippers find pot of gold
Pharma pink-slippers find pot of gold
Six years after founding company for downsized R&D scientists, Boston Biomedical is acquired by Japanese pharma DSP for $2.63 billion
Commentary
Completing the picture with regulatory information management
Completing the picture with regulatory information management
Pharmaceutical companies depend on data to bring products to market, but companies struggle to cohesively and coherently manage all that data and all that information.
Taking inventory of life-science headcounts
Taking inventory of life-science headcounts
Survival requires innovating again and again at a greater and greater speed. Customers create jobs. No one else can.
Editor's Focus
The little biotech that could
The little biotech that could
Dr. Chiang Li is not the kind of guy you’d expect to be living on a minimum-wage salary. The Harvard Medical School graduate with more than 60 inventions to his name and founder of Boston Biomedical Inc. chose to subsist on a meager salary for the last six years. Why? Read on for his remarkable story of innovation and sacrifice.
